Why the study?
Do long-acting antihypertensive agents reduce cardiovascular morbidity and mortality in hypertensive patients with coronary artery disease?
Do long-acting antihypertensive agents reduce cardiovascular morbidity and mortality in hypertensive patients with coronary artery disease?
Chronobiology suggests that long-acting antihypertensive agents may optimize therapy and reduce cardiovascular risk in patients with hypertension and CAD.
Should not yet change practice in hypertensive CAD; leaves open prospective confirmation of chronobiology-guided long-acting agents.
Hypertension, a major risk factor for cardiovascular disease worldwide, remains inadequately diagnosed and treated, particularly in certain at-risk populations. Hypertension, often in association with other factors, increases the risk for the development of coronary artery disease (CAD). In turn, CAD increases the risk for related morbidity and mortality and presents treatment challenges. The chronobiology of many cardiovascular events offers a pathway for selecting optimal therapy for the hypertensive patient with CAD. Choosing a long-acting agent that achieves high plasma drug levels during critical hours may reduce the risk for cardiovascular morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Suzanne Oparil (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: